


**Amendments to the Claims**

Please cancel Claims 2, 6 and 7. Please amend Claim 1. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently amended) ~~A~~ An injectable sustained release composition comprising a poly(lactide-co-glycolide) ~~biocompatible, biodegradable~~ polymer having incorporated therein a bisphosphonate compound of Formula I or a pharmaceutically acceptable salt thereof:



wherein;

$R_1$  is independently, H, alkyl, aryl or heteroaryl;

X is H,  $-OR_1$  or halogen;


$R_2$  is H,  $\Theta$ , S, N,  $(CH_2)_n$ , branched alkylene, branched or straight alkenylene or alkynylene;

n is an integer from about 0 to about 18;

Y is H,  ~~$R_1$ , halogen, alkyl, aryl, heteroaryl~~, amino, cyano or amido group; and wherein the composition is in the form of a microparticle.


2. (Cancelled)
3. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:

-4-




or a pharmaceutically acceptable salt thereof.

4. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:



or a pharmaceutically acceptable salt thereof.

5. (Original) The sustained release composition of Claim 1, wherein the bisphosphonate compound has the following structure:



or a pharmaceutically acceptable salt thereof.

6. (Canceled)
7. (Canceled)
8. The sustained release composition of Claim 1, wherein the bisphosphonate is present from about 0.5% (w/w) to about 20% (w/w) of the total weight of the composition.